Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Schmidt

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Brain Research|September 12, 2003
Immunohistochemical localization of PDE10A in the rat brainThomas F Seeger, Brenda Bartlett, Timothy M Coskran, et al.
Journal of Medicinal Chemistry|July 28, 2009
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophreniaPatrick R Verhoest, Douglas S Chapin, Michael Corman, et al.
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
ACS Chemical Neuroscience|October 8, 2016
Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side EffectsTravis T Wager, Thomas Chappie, David Horton, et al.
Journal of Medicinal Chemistry|March 4, 2011
1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosisLei Zhang, Michael A Brodney, John Candler, et al.
Neuropharmacology|July 19, 2011
Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brainChristine A Strick, Cheryl Li, Liam Scott, et al.
Journal of Medicinal Chemistry|June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophreniaChristopher J Helal, Zhijun Kang, Xinjun Hou, et al.
Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2022
First-in-Human Evaluation of <sup>18</sup>F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4BYuichi Wakabayashi, Per Stenkrona, Ryosuke Arakawa, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Brain Research|September 12, 2003
Immunohistochemical localization of PDE10A in the rat brainThomas F Seeger, Brenda Bartlett, Timothy M Coskran, et al.
Journal of Medicinal Chemistry|July 28, 2009
Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophreniaPatrick R Verhoest, Douglas S Chapin, Michael Corman, et al.
Journal of Medicinal Chemistry|July 12, 2012
Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disordersPatrick R Verhoest, Kari R Fonseca, Xinjun Hou, et al.
Journal of Medicinal Chemistry|November 19, 2009
Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategyPatrick R Verhoest, Caroline Proulx-Lafrance, Michael Corman, et al.
ACS Chemical Neuroscience|October 8, 2016
Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side EffectsTravis T Wager, Thomas Chappie, David Horton, et al.
Journal of Medicinal Chemistry|March 4, 2011
1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosisLei Zhang, Michael A Brodney, John Candler, et al.
Neuropharmacology|July 19, 2011
Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brainChristine A Strick, Cheryl Li, Liam Scott, et al.
Journal of Medicinal Chemistry|June 10, 2011
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophreniaChristopher J Helal, Zhijun Kang, Xinjun Hou, et al.
Journal of Medicinal Chemistry|October 3, 2012
Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsMichelle M Claffey, Christopher J Helal, Patrick R Verhoest, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 30, 2022
First-in-Human Evaluation of <sup>18</sup>F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4BYuichi Wakabayashi, Per Stenkrona, Ryosuke Arakawa, et al.
Pageof 5